BioSpace News Archive

Cara Therapeutics, Inc. announced that the Company will host a conference call and live audio webcast on Thursday, February 27, 2020, at 4:30 p.m. ET to report fourth quarter and full year 2019 financial results and provide a corporate update.

Corcept Therapeutics Incorporated reported its results for the quarter ended December 31, 2019.

Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020

BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration has accepted for Priority Review the Biologics License Application to the FDA for its investigational AAV5 gene therapy, valoctocogene roxaparvovec, for adults with hemophilia A.

NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced financial results for the quarter and full year ended Dec. 31, 2019.

Xeris Pharmaceuticals, Inc. announced that, in connection with its previously announced underwritten public offering of shares of common stock, the underwriters partially exercised their option to purchase an additional 1,299,769 shares of common stock from the Company out of the 1,350,000 total shares underlying the option.

Universal Display Corporation, enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, announced that its Board of Directors approved an increased first quarter cash dividend of $0.15 per share on the Company’s common stock, up from the previous quarter’s dividend of $0.10 per share.

Globus Medical, Inc., a leading musculoskeletal solutions company, announced its financial results for the fourth quarter and year ended December 31, 2019.

Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.18 per share of its common stock, payable on April 24, 2020 to holders of record on March 27, 2020.

Westport, CT, Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it intends to offer shares of its common stock in a “best efforts” underwritten public offering. The offering is subject to market and other conditions and there ca